A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis

References

• WHO. Global tuberculosis report 2014. Geneva: World health organization, 2014. http://www.who.int/tb/publications/global_report/en/ (accessed Nov 12, 2014).
   Google Scholar
• Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis 2002; 185:401-4; PMID:11807725; http://dx.doi.org/10.1086/338342
   PubMed Web of Science ®Google Scholar
• Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3:656-62; PMID:16012514; http://dx.doi.org/10.1038/nrmicro1211
   PubMed Web of Science ®Google Scholar
• Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. Chem Med Chem 2013; 8:360-76; PMID:23316023; http://dx.doi.org/10.1002/cmdc.201200487
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitie MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O, et al. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013; 31:2196-206; PMID:22643213; http://dx.doi.org/10.1016/j.vaccine.2012.05.035
   PubMed Web of Science ®Google Scholar
• Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Bigbee M, Milk L, Gideon HP, Rodgers M, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012; 122:303-14; PMID:22133873; http://dx.doi.org/10.1172/JCI46252
   PubMed Web of Science ®Google Scholar
• Junqueira-Kipnis AP, Marques Neto LM, Kipnis A. Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines. Front Immunol 2014; 5:188; PMID:24795730; http://dx.doi.org/10.3389/fimmu.2014.00188
   PubMed Web of Science ®Google Scholar
• Orme IM. Vaccine development for tuberculosis: current progress. Drugs 2013; 73:1015-24; PMID:23794129; http://dx.doi.org/10.1007/s40265-013-0081-8
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Tuberculosis vaccines: time to think about the next generation. Semin Immunol 2013; 25:172-81; PMID:23706597; http://dx.doi.org/10.1016/j.smim.2013.04.006
   PubMed Web of Science ®Google Scholar
• Andersen P, Kaufmann SH. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspecti Med 2014; 4: 1–19; PMID:24890836
   PubMedGoogle Scholar
• Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther 2007; 82:595-600; PMID:17898708; http://dx.doi.org/10.1038/sj.clpt.6100362
   PubMed Web of Science ®Google Scholar
• Geluk A, Lin MY, van Meijgaarden KE, Leyten EM, Franken KL, Ottenhoff TH, Klein MR. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun 2007; 75:2914-21; PMID:17387166; http://dx.doi.org/10.1128/IAI.01990-06
   PubMed Web of Science ®Google Scholar
• Andersen P, Woodworth JS. Tuberculosis vaccines–rethinking the current paradigm. Trend Immunol 2014; 35:387-95; PMID:24875637; http://dx.doi.org/10.1016/j.it.2014.04.006
   PubMed Web of Science ®Google Scholar
• Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 2007; 15:7-13; PMID:17141504; http://dx.doi.org/10.1016/j.tim.2006.11.008
   PubMed Web of Science ®Google Scholar
• Pallen MJ. The ESAT-6/WXG100 superfamily – and a new Gram-positive secretion system? Trends Microbiol 2002; 10:209-12; PMID:11973144; http://dx.doi.org/10.1016/S0966-842X(02)02345-4
   PubMed Web of Science ®Google Scholar
• Sreejit G, Ahmed A, Parveen N, Jha V, Valluri VL, Ghosh S, Mukhopadhyay S. The ESAT-6 protein of Mycobacterium tuberculosis interacts with beta-2-microglobulin (beta2M) affecting antigen presentation function of macrophage. PLoS pathogens 2014; 10:e1004446; PMID:25356553; http://dx.doi.org/10.1371/journal.ppat.1004446
   PubMed Web of Science ®Google Scholar
• Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004; 72:6148-50; PMID:15385521; http://dx.doi.org/10.1128/IAI.72.10.6148-6150.2004
   PubMed Web of Science ®Google Scholar
• Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276:1420-2; PMID:9162010; http://dx.doi.org/10.1126/science.276.5317.1420
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, Izzo AA, Barker LF. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 2012; 30:2811-23; PMID:22387630; http://dx.doi.org/10.1016/j.vaccine.2012.02.036
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 2012; 92 Suppl 1:S6-13; PMID:22441160; http://dx.doi.org/10.1016/S1472-9792(12)70005-7
   PubMed Web of Science ®Google Scholar
• Coler RN, Skeiky YA, Vedvick T, Bement T, Ovendale P, Campos-Neto A, Alderson MR, Reed SG. Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J Immunol 1998; 161:2356-64; PMID:9725231
   PubMed Web of Science ®Google Scholar
• Coler RN, Campos-Neto A, Ovendale P, Day FH, Fling SP, Zhu L, Serbina N, Flynn JL, Reed SG, Alderson MR. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol 2001; 166:6227-35; PMID:11342645; http://dx.doi.org/10.4049/jimmunol.166.10.6227
   PubMed Web of Science ®Google Scholar
• Xin Q, Niu H, Li Z, Zhang G, Hu L, Wang B, Li J, Yu H, Liu W, Wang Y, et al. Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PloS one 2013; 8:e72745; PMID:23967337; http://dx.doi.org/10.1371/journal.pone.0072745
   PubMed Web of Science ®Google Scholar
• Rosenkrands I, Slayden RA, Crawford J, Aagaard C, Barry CE, 3rd, Andersen P. Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol 2002; 184:3485-91; PMID:12057942; http://dx.doi.org/10.1128/JB.184.13.3485-3491.2002
   PubMed Web of Science ®Google Scholar
• Shi L, Jung YJ, Tyagi S, Gennaro ML, North RJ. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci U S A 2003; 100:241-6; PMID:12506197; http://dx.doi.org/10.1073/pnas.0136863100
   PubMed Web of Science ®Google Scholar
• Davidow A, Kanaujia GV, Shi L, Kaviar J, Guo X, Sung N, Kaplan G, Menzies D, Gennaro ML. Antibody profiles characteristic of Mycobacterium tuberculosis infection state. Infect Immun 2005; 73:6846-51; PMID:16177363; http://dx.doi.org/10.1128/IAI.73.10.6846-6851.2005
   PubMed Web of Science ®Google Scholar
• Niu H, Peng J, Bai C, Liu X, Hu L, Luo Y, Wang B, Zhang Y, Chen J, Yu H, et al. Multi-stage tuberculosis subunit vaccine candidate LT69 provides high protection against mycobacterium tuberculosis infection in mice. PLoS One 2015; 10:e0130641; PMID:26098302; http://dx.doi.org/10.1371/journal.pone.0130641
   PubMed Web of Science ®Google Scholar
• Wang CC, Zhu B, Fan X, Gicquel B, Zhang Y. Systems approach to tuberculosis vaccine development. Respirology 2013; 18:412-20; PMID:23331331; http://dx.doi.org/10.1111/resp.12052
   PubMed Web of Science ®Google Scholar
• Coppola M, van den Eeden SJ, Wilson L, Franken KL, Ottenhoff TH, Geluk A. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis. Clin Vaccine Immunol 2015; 22:1060-9; PMID:26202436; http://dx.doi.org/10.1128/CVI.00271-15
   PubMed Web of Science ®Google Scholar
• Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 2015; 33:4130-40; PMID:26095509; http://dx.doi.org/10.1016/j.vaccine.2015.06.051
   PubMed Web of Science ®Google Scholar
• Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med 1999; 189:1973-80; PMID:10377193; http://dx.doi.org/10.1084/jem.189.12.1973
   PubMed Web of Science ®Google Scholar
• Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, Shen Y, Halliday L, Fortman J, McAllister M, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS pathogens 2009; 5:e1000392; PMID:19381260; http://dx.doi.org/10.1371/journal.ppat.1000392
   PubMed Web of Science ®Google Scholar
• Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11:321-33; PMID:10959079; http://dx.doi.org/10.1016/S1359-6101(00)00010-1
   PubMed Web of Science ®Google Scholar
• Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11:343-54; PMID:21475309; http://dx.doi.org/10.1038/nri2960
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Holmes J, Katona IM, Urban JF, Jr., Beckmann MP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8:303-33; PMID:1693082; http://dx.doi.org/10.1146/annurev.iy.08.040190.001511
   PubMed Web of Science ®Google Scholar
• Orme IM. Current progress in tuberculosis vaccine development. Vaccine 2005; 23:2105-8; PMID:15755579; http://dx.doi.org/10.1016/j.vaccine.2005.01.062
   PubMed Web of Science ®Google Scholar
• Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH. Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses. Front Immunol 2014; 5:256; PMID:25009541; http://dx.doi.org/10.3389/fimmu.2014.00256
   PubMed Web of Science ®Google Scholar
• Niu H, Hu L, Li Q, Da Z, Wang B, Tang K, Xin Q, Yu H, Zhang Y, Wang Y, et al. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine 2011; 29:9451-8; PMID:22024175; http://dx.doi.org/10.1016/j.vaccine.2011.10.032
   PubMed Web of Science ®Google Scholar